New combo attack on lung cancer brain metastases shows promise in Real-World study
NCT ID NCT07491211
First seen Mar 26, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This study looks at using a targeted drug called osimertinib together with precise brain radiation as the first treatment for people with a certain type of lung cancer (EGFR-mutant) that has spread to the brain and causes symptoms. Researchers reviewed medical records of 300 patients from multiple hospitals to see how well this combination works and how safe it is. The goal is to find a better way to control both the lung cancer and brain tumors from the start.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China, 200032, China
-
Shanghai Jiao Tong University Affiliated Chest Hospital
Shanghai, China
-
Wuhan Tongji Hospital
Wuhan, Hubei, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osimertinib (a targeted cancer pill) and intracranial stereotactic radiotherapy (precise radiation to brain tumors)
What this could lead to
If successful, this combination could become a standard first treatment for people with EGFR-mutant lung cancer that has spread to the brain, potentially improving control of brain tumors and extending survival.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be less reliable. The treatment involves radiation to the brain, which carries risks like swelling or tissue damage. It is also only for patients with a specific gene mutation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.